Gilead Sciences (FRA:GIS) Research & Development: €4,979 Mil (TTM As of Mar. 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €108.26
GF Value €82.28
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Research & Development?

Gilead Sciences FRA:GIS -0.79% 75 Research & Development is €4,979 Mil as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.28 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gilead Sciences's Research & Development for the three months ended in Mar. 2026 was €1,187 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €4,979 Mil.

Gilead Sciences  (FRA:GIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gilead Sciences Research & Development Related Terms

Gilead Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Research & Development Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,071.89 4,698.29 5,243.41 5,641.19 4,952.35

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,275.58 1,292.70 1,146.79 1,352.74 1,186.78
FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,979 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €4,979 Mil mean?
Gilead Sciences (FRA:GIS) has a Research & Development of €4,979 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Research & Development too high?
Gilead Sciences' current Research & Development is €4,979 Mil. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Research & Development compare to AMGN and PFE?
Gilead Sciences' Research & Development of €4,979 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Research & Development is €4,979 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.28, compared to a current price of €108.26 — trading 31.6% above its estimated fair value. The current Research & Development is €4,979 Mil. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Research & Development is €4,979 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €108.26 is trading 31.6% above its estimated GF Value™ of €82.28. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Research & Development: €4,979 Mil
  • GF Value™: €82.28 vs. price of €108.26 (31.6% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€108.26
Price
€82.28
GF Value